Dottikon ES Holding AG (DESN.SW) fair value

ACCE thesis

Dottikon ES Holding makes fluorinated and other specialty fine chemicals, mostly custom-manufactured intermediates and active pharmaceutical ingredients for agrochemical and pharma customers under multi-year contracts. Its edge is process know-how in fluorination chemistry, which few contract manufacturers can run safely at scale, and the 61% gross margin and 27% operating margin show the pricing that comes with it. Revenue growth is only 3.0%, so the case rests on capacity additions and on customers moving more of their product pipelines into the Swiss plant rather than on any sudden demand surge. The stock carries a 38x trailing and 30x forward P/E against a 9.9% ROE, so the valuation asks for sustained execution that the current top line does not yet demonstrate. It is small, illiquid and not in any major index, which means the shares can move on little volume and deserve a deeper look at utilization, backlog and customer concentration before any sizing decision.